Company: ANTX
Filing Date: 2025-03-25
Form Type: 10-K
Source: 0000950170-25-044366
Chunk: 150

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-03-25
Form: 10-K
Item: Item 1B
Chunk 150
---
 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. 

Not applicable. 

88

PART III 

Item 10. Directors, Executive Officers and Corporate Governance. 

The information required by this item is incorporated by reference to the Proxy Statement to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, 2024.

We have adopted insider trading policies and procedures governing the purchase, sale and other dispositions of our securities by directors, officers and employees that are designed to promote compliance with insider trading laws, rules and regulations, and applicable Nasdaq listing standards, as well as procedures designed to further the foregoing purposes. A copy of our insider trading policy is filed with this Annual Report on Form 10-K as Exhibit 19.1.

Item 11. Executive Compensation. 

The information required by this item is incorporated by reference to the Proxy Statement to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, 2024.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The information required by this item is incorporated by reference to the Proxy Statement to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, 2024.

Item 13. Certain Relationships and Related Transactions, and Director Independence.

The information required by this item is incorporated by reference to the Proxy Statement to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, 2024.

Item 14. Principal Accounting Fees and Services.

The information required by this item is incorporated by reference to the Proxy Statement to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, 2024.

89

PART IV 

Item 15. Exhibits, Financial Statement Schedules. 

(a)The following documents are filed as a part of this Annual Report:

(1)Financial Statements:

    Report of Independent Registered Public Accounting Firm (PCAOB ID: 238)
    F-2

    Balance Sheets as of December 31, 2024 and 2023
    F-3

    Statements of Operations and Comprehensive Loss for the years ended December 31, 2024 and 2023
    F-4

    Statements of Stockholders’ Equity for the years ended December 31, 2024 and 2023
    F-5